Overview

Castle Biosciences is a leading diagnostics company that provides personalized, clinically actionable information to clinicians and patients to inform treatment decisions and improve health outcomes. The Company is focused on transforming the disease management paradigm in skin cancer and other diseases with high clinical need by leveraging advanced technologies for its portfolio of innovative diagnostic tests.

Read More

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma and Barrett’s esophagus. Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile, or GEP, test that more accurately predicts a patient’s risk of metastasis or recurrence as well as sentinel lymph node positivity. DecisionDx®-SCC is our GEP test that predicts the risk of metastasis for patients with cutaneous squamous cell carcinoma, who have one or more risk factors. DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Our comprehensive diagnostic offering — myPath® Melanoma and DecisionDx® DiffDx™-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions.

In December of 2021, Castle acquired Cernostics, Inc., and the TissueCypher® Barrett’s Esophagus test, expanding Castle’s estimated U.S. total addressable market by approximately $1 billion. The TissueCypher Barrett’s Esophagus test is the first precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barrett’s esophagus (BE).

Castle has active research and development programs for tests in other dermatologic diseases with unmet clinical need, including its test in development to predict systemic therapy response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. If successful, our pipeline tests will add approximately $3.6 billion to our estimated U.S. total addressable market.

Read Less

Why Invest

Man looking at slide sample
Culture of teamwork and innovation
Suite of dermatologic prognostic and diagnostic tests
Expansive body of evidence
Strong financial position
Robust pipeline

Q3 2021 Results

Latest News